Updated CRC Screening Test Results to Debut October 14
New colorectal cancer screening data may offer improved detection rates for precancerous lesions in U.S. adults.
Updated on Oct. 11, 2026 in Cancer
Live Poll
Do you trust non-invasive blood tests as a reliable alternative to traditional cancer screening methods?
Freenome will present updated validation data for its SimpleScreen CRC test on October 14, 2026, at the ACG meeting in Nashville. This update follows the commercial launch of the company's first-generation colorectal cancer screening test in the United States last September.
Why it matters
Improving screening accuracy for precancerous lesions is vital for early intervention and cancer prevention. This update reflects the company's iterative methodology to enhance the performance of its existing screening tools.
In a pivotal clinical validation study adjusted for U.S. Census demographics, the updated test reached 80.4% sensitivity for colorectal cancer and 90% specificity for colonoscopy findings. The findings indicate improved detection of precancerous lesions compared to previous benchmarks.
The players
Freenome
A biotechnology company headquartered in Brisbane, California, focused on developing blood-based cancer screening tests.
Aasma Shaukat
A gastroenterologist and researcher scheduled to present the updated clinical trial findings.
The details
The SimpleScreen CRC test uses a proprietary algorithm to analyze biological markers, which the company iterates to improve performance over time. The latest validation assesses both assay and algorithm improvements to better identify high-grade dysplasia and advanced precancerous lesions before they progress. Researchers adjusted these results to match the age and sex distribution of the U.S. Census, providing a clearer look at how the test functions within the general adult population.
Timeline
• June 2, 2025: The original PREEMPT CRC study was published in JAMA.
• July 2026: The FDA approved the first-generation SimpleScreen CRC test.
• September 2026: The test launched commercially in the United States.
• October 14, 2026: Dr. Aasma Shaukat will present the updated results at the ACG meeting.
Health Landscape
This development represents an advancement in non-invasive colorectal cancer screening, building upon the baseline established by the 2025 PREEMPT CRC study. It reflects an industry-wide trend of refining multi-target screening assays to improve sensitivity for precancerous stages.
While these test improvements offer potential benefits for early detection, the choice of screening method remains a personal decision to be discussed with your physician. Ask your doctor how different screening modalities, including blood-based tests and colonoscopies, compare based on your personal risk factors.
The takeaway
Advancements in screening technology aim to catch colorectal abnormalities earlier, potentially improving long-term outcomes. Discuss your current screening options and any concerns about your digestive health with your primary care provider or a gastroenterologist.
What happens next
The clinical validation data is scheduled for presentation as late-breaking research at the American College of Gastroenterology (ACG) meeting on October 14, 2026.
Further reading
Learn more about the latest innovations in Cancer prevention and screening technology.
More information
Find additional details on the test and the company's research at the Freenome company and product information portal.
Live Poll
Do you trust non-invasive blood tests as a reliable alternative to traditional cancer screening methods?
